Clinical Trial Update: A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

CM326 is being evaluated in a Phase II trial for moderate to severe chronic obstructive pulmonary disease, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CM326

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: RECRUITING